Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

DSpace/Manakin Repository

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Citable link to this page

 

 
Title: Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease
Author: Greenberg, Steven A.; Zivadinov, R.; Lee-Kwen, P.; Sharma, Jitendra; Planter, M.; Umhauer, M.; Glenister, N.; Bakshi, Rohit

Note: Order does not necessarily reflect citation order of authors.

Citation: Greenberg, S. J., R. Zivadinov, P. Lee-Kwen, J. Sharma, M. Planter, M. Umhauer, N. Glenister, and R. Bakshi. 2016. “Fludarabine Add-on Therapy in Interferon-Beta-Treated Patients with Multiple Sclerosis Experiencing Breakthrough Disease.” Therapeutic Advances in Neurological Disorders (January 21). doi:10.1177/1756285615626049.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: Background: Patients with relapsing–remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulatory therapy to control active multiple sclerosis (MS).
Objective: The objective of this study was to explore the safety and tolerability of FLU versus monthly methylprednisolone (MP) in IFNβ-treated RRMS patients with breakthrough disease. Clinical and MRI effects of IFNβ-1a plus FLU were evaluated.
Methods: Eighteen patients with breakthrough disease [⩾2 relapses over the prior year and ⩾1.0-point increase in Expanded Disability Status Scale (EDSS) score sustained for ⩾3 months] after >1 year of IFNβ therapy were enrolled in this prospective, open-label, randomized, proof-of-concept, pilot study. Patients received intravenous (IV) MP 1 g daily for 3 days and then were randomized to receive 3 monthly IV infusions of FLU 25 mg/m2 daily for 5 consecutive days (n = 10) or MP 1 g (n = 8). All patients maintained their intramuscular IFNβ-1a treatment throughout the study. Analyses explored safety signals and directional trends; this preliminary study was not powered to detect clinically meaningful differences.
Results: Both combination treatments were safe and well tolerated, with all adverse events mild. Patients treated with IFNβ-1a plus FLU had similar relapse rates, EDSS scores, and MS Functional Composite scores, but significantly less acute corticosteroid use for on-study relapses and better responses on some MRI outcomes, versus patients treated with IFNβ-1a plus MP.
Conclusions: Further study of FLU for breakthrough disease in patients with RRMS is warranted.
Published Version: doi:10.1177/1756285615626049
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29425093
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters